Persyst 14 EEG Review and Analysis Software

Persyst 14 EEG Review and Analysis Software is designed to assist clinicians by processing EEG recordings to automatically identify potential seizure and spike events, quantify EEG characteristics, and reduce common artifacts. Its methodology relies on analyzing scalp EEG data to provide supplementary information for neurological assessment, always requiring expert interpretation of the original waveforms and not offering standalone diagnostic conclusions.

Persyst 14 EEG Review and Analysis Software is a tool intended for qualified medical practitioners to aid in the review, monitoring, and analysis of electroencephalogram (EEG) recordings. The software processes EEG data acquired through scalp electrodes using the standard 10/20 system. Its primary functionalities include marking previously acquired EEG sections that may correspond to electrographic seizures in adults (18 years and older) and spikes in patients from one month of age. Furthermore, it calculates and displays various quantitative EEG measures such as FFT, Rhythmicity, Peak Envelope, Artifact Intensity, Amplitude, Relative Symmetry, and Suppression Ratio, all of which require interpretation in conjunction with the original EEG waveforms. The software also incorporates Persyst AR for reducing EMG, eye movement, and electrode artifacts, though it may modify cerebral activity waveforms and doesn't eliminate all artifacts. It features an aEEG (amplitude-integrated EEG) display for monitoring brain state and can show physiological signals, including heart rate derived from the EEG's ECG channel (not for patients with pacemakers). Persyst 14 provides notifications for seizure detection, quantitative EEG, and aEEG during acquisition processing, with potential delays; these are not substitutes for real-time expert monitoring. The device explicitly does not offer diagnostic conclusions, emphasizing that all interpretations must be made by qualified clinicians referencing the original EEG data.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What is the validated sensitivity and specificity of the Seizure Detection component in diverse adult populations, particularly for non-convulsive seizures or those with subtle electrographic manifestations?; How does the Persyst AR artifact reduction algorithm differentiate between complex artifacts (e.g., EMG, eye movement) and genuine cerebral activity, especially in low amplitude or noisy EEG recordings, and what is its impact on subsequent quantitative analysis?; What is the comparative performance of the Spike Detection component across different pediatric age groups (especially near the one-month limit) and for various interictal epileptiform discharge morphologies?; What is the typical latency and reliability of the notification system (on-screen and email) for seizure detection and critical qEEG changes in a real-world, networked clinical environment, and how might this affect timely clinical response?; Are there specific EEG patterns or patient conditions where the quantitative EEG measures (e.g., Rhythmicity, Suppression Ratio) provided by Persyst 14 have demonstrated superior clinical utility in aiding assessment compared to traditional visual review alone?